Incyte Corporation

Kaijiong Xiao

Wenqing Yao

Liangxing Wu

Ding-Quan Qian

Wenyu Zhu

Chunhong He

Song Mei

Fenglei Zhang

Zhenwu Li

Meizhong Xu

Liang Lu

Haisheng Wang

Jingwei Li

Chao Qi

Neil Lajkiewicz

Yingda Ye

Zhiyong Yu

Leah C Konkol

Joshua Hummel

Yingnan Chen

Min Ye

Margaret Favata

Yvonne Lo

Phillip C Liu

Jeffrey C Yang

Alla Volgina

Nina Zolotarjova

Richard Wynn

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.

Heterocyclic compounds as immunomodulators

The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.

Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors

Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. 

Compositions and methods for inducing PD-L1 internalization are disclosed. The methods include reducing the amount of cell surface PD-L1 by contacting a cell expressing PD-L1 with a compound that binds to cell surface PD-L1 and induces PD-L1 internalization. Compounds that induce PD-L1 internalization can be used to enhance, stimulate and/or increase an immune response and treat a PD-1-related disease or condition.

Immunomodulator compounds and methods of use

Growing community of inventors

Clark, NJ, United States of America

Kaijiong Xiao